Pfiz­er prunes three drugs from its pipeline; Astel­las in-li­cens­es ear drug

• Pfiz­er’s lat­est pipeline up­date comes with a no­tice of three mid­night pro­gram ex­e­cu­tions. The phar­ma gi­ant has pruned three drugs from its sub­stan­tial pipeline, ac­cord­ing to the up­date. The most ad­vanced is a Phase II di­a­betes pro­gram for PF-06291874; fol­lowed by the ear­ly stage car­dio drug PF-06815345 (hy­per­lipi­demia) as well as the neu­ro drug PF-06412562, al­so in Phase I. None of these were high pro­file projects, none of the ter­mi­na­tions were ex­plained.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.